Nucleai For Profit
Step into the World of AI-Driven Spatial Biomarkers. Your next-gen cancer treatments need better companions. Advance your ADC, bispecific, and immunotherapy programs with a next-gen diagnostic strategy. Join us at IO360
Total Funding:
46500000
Headquarters:
Tel Aviv, Tel Aviv, Israel
Funding Status:
Early Stage Venture
Employee Number:
51-100
Estimated Revenue:
$4.8Mper year
Last Funding Type:
Series B
Technology:
AI-driven
Last Funding Date:
2022-03-22
Investors Number:
7
Founded Date:
2017-01-01
Industry:
Deep Diagnostics